120 related articles for article (PubMed ID: 11126398)
1. The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex.
Ruiu S; Marchese G; Saba PL; Gessa GL; Pani L
Mol Psychiatry; 2000 Nov; 5(6):673-7. PubMed ID: 11126398
[TBL] [Abstract][Full Text] [Related]
2. Effects of ritanserin on haloperidol-induced dopamine (D2) receptor up-regulation in the rat.
Szczepanik AM; Wilmot CA
Neurosci Lett; 1997 Aug; 231(2):91-4. PubMed ID: 9291148
[TBL] [Abstract][Full Text] [Related]
3. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system.
Andersson JL; Nomikos GG; Marcus M; Hertel P; Mathé JM; Svensson TH
Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct; 352(4):374-85. PubMed ID: 8532065
[TBL] [Abstract][Full Text] [Related]
4. Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats.
Okada T; Shioda K; Makiguchi A; Suda S
Int J Neuropsychopharmacol; 2020 Dec; 23(12):811-820. PubMed ID: 32821948
[TBL] [Abstract][Full Text] [Related]
5. 5-HT2 receptor regulation of acetylcholine release induced by dopaminergic stimulation in rat striatal slices.
Ramírez MJ; Cenarruzabeitia E; Lasheras B; Del Rio J
Brain Res; 1997 May; 757(1):17-23. PubMed ID: 9200494
[TBL] [Abstract][Full Text] [Related]
6. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
Li Z; Huang M; Prus AJ; Dai J; Meltzer HY
Brain Res; 2007 Feb; 1134(1):70-8. PubMed ID: 17207474
[TBL] [Abstract][Full Text] [Related]
7. The serotonin 5-HT(2A) receptor subtype does not mediate apomorphine-induced aggressive behaviour in male Wistar rats.
Skrebuhhova-Malmros T; Pruus K; Rudissaar R; Allikmets L; Matto V
Pharmacol Biochem Behav; 2000 Oct; 67(2):339-43. PubMed ID: 11124399
[TBL] [Abstract][Full Text] [Related]
8. Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex.
Pehek EA
Synapse; 1996 Sep; 24(1):12-8. PubMed ID: 9046072
[TBL] [Abstract][Full Text] [Related]
9. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM
Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the effects of risperidone, raclopride, and ritanserin on intravenous self-administration of d-amphetamine.
Fletcher PJ
Pharmacol Biochem Behav; 1998 May; 60(1):55-60. PubMed ID: 9610924
[TBL] [Abstract][Full Text] [Related]
11. Effect of atypical antipsychotic drugs on 5-HT2 receptors in the rat orbito-frontal cortex: an in vivo electrophysiological study.
Bergqvist PB; Dong J; Blier P
Psychopharmacology (Berl); 1999 Mar; 143(1):89-96. PubMed ID: 10227084
[TBL] [Abstract][Full Text] [Related]
12. Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone.
Leysen JE; Van Gompel P; Gommeren W; Woestenborghs R; Janssen PA
Psychopharmacology (Berl); 1986; 88(4):434-44. PubMed ID: 3010361
[TBL] [Abstract][Full Text] [Related]
13. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain.
Hertel P; Nomikos GG; Iurlo M; Svensson TH
Psychopharmacology (Berl); 1996 Mar; 124(1-2):74-86. PubMed ID: 8935802
[TBL] [Abstract][Full Text] [Related]
14. Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin.
Kitaichi K; Yamada K; Hasegawa T; Furukawa H; Nabeshima T
Jpn J Pharmacol; 1994 Oct; 66(2):181-9. PubMed ID: 7532732
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of quinpirole and 7-OH-DPAT on the spontaneous [(3)H]-dopamine efflux from rat striatal synaptosomes.
García-Sanz A; Badia A; Clos MV
Synapse; 2001 Apr; 40(1):65-73. PubMed ID: 11170223
[TBL] [Abstract][Full Text] [Related]
16. Biochemical profile of risperidone, a new antipsychotic.
Leysen JE; Gommeren W; Eens A; de Chaffoy de Courcelles D; Stoof JC; Janssen PA
J Pharmacol Exp Ther; 1988 Nov; 247(2):661-70. PubMed ID: 2460616
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
[TBL] [Abstract][Full Text] [Related]
18. Serotonin-2 and dopamine-1 binding components of clozapine in frontal cortex and striatum in the human brain visualized by positron emission tomography.
Lundberg T; Lindström L; Hartvig P; Reibring L; Agren H; Lundqvist H; Fasth KJ; Antoni G; Långström B
Psychiatry Res; 1996 May; 67(1):1-10. PubMed ID: 8797237
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the role of 5-HT(2) receptor antagonism during subchronic antipsychotic drug administration in rats.
Kruzich PJ; See RE
Brain Res; 2000 Sep; 875(1-2):35-43. PubMed ID: 10967296
[TBL] [Abstract][Full Text] [Related]
20. Ritanserin administration potentiates amphetamine-stimulated dopamine release in the rat prefrontal cortex.
Pehek EA; Bi Y
Prog Neuropsychopharmacol Biol Psychiatry; 1997 May; 21(4):671-82. PubMed ID: 9194148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
